Clinical Trial · NCT07140315

An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1

Overview

This Phase 1 clinical trial will test a new drug called [18F]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the body, how long it stays in the body, and how much radiation it gives off. [18F]DK222 is designed to attach strongly and specifically to a protein called PD-L1, which helps cancer hide from the immune system.

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase

Phase 1

Contacts

Mehreen Nabi

mnabi1@jh.edu

14109296586

ClinicalTrials.gov

NCT07140315

Drug / Compound

[18F]DK222

Isotope(s):

Target(s):

PD-L1

Ligand Class: Peptides